Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L

NCT01348490 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01348490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01348490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2011
Completion date
December 19, 2018
Enrollment
66 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

mpn (myeloproliferative neoplasms)